2 Modok S, Mellor H R, Chllaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. CurrOpin Pharmacol, 2006, 6: 350-354
[2]
3 Van Der Kolk D M, De Vries E G E, Muller M, et al. The role of drug efflux pumps in acute myeloid leukemia. Leukemia Lymphoma, 2002,43: 685-701？？
[3]
4 Ravna A W, Sager G. Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4). Bioorg MedChem Lett, 2008, 18: 3481-3483？？
[4]
7 Steinbach D, Wittig S, Cario G, et al. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhoodALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood, 2003, 102: 4493-4498？？
[5]
8 Peng X X, Shi Z, Damaraju V L, et al. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquiredresistance to 6-mercaptopurine. Leukemia Res, 2008, 32: 799-809？？
[6]
9 Huynh T, W？lchli S, Sioud M. Transcriptional targeting of small interfering RNAs into cancer cells. Biochem Biophys Res Commun, 2006,350: 854-859？？
[7]
10 Liao W, Ning G. Knockdown of apolipoprotein B, an atherogenic apolipoprotein, in HepG2 cells by lentivirus-mediated siRNA. BiochemBiophys Res Commun, 2006, 344: 478-483
[8]
11 Numnum T M, Makhija S, Lu B, et al. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interferencein ovarian carcinoma cell lines. Gynecol Oncol, 2008, 108: 34-41？？
[9]
12 Jung C R, Yoo J S, Jang Y J, et al. Adenovirus-mediated transfer of sirna against PTTG1 inhibits liver cancer cell growth in vitro and in vivo.Hepatology, 2006, 43: 1042-1052？？
[10]
13 Cioca D P, Aoki Y, Kiyosawa K. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines.Cancer Gene Ther, 2003, 10: 125-133？？
[11]
14 Rubinson D A, Dillon C P, Kwiatkowski A V, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stemcells and transgenic mice by RNA interference. Nat Genet, 2003, 33: 401-406？？
[12]
15 Brummelkamp T P, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science, 2002, 296:550-553？？
[13]
16 Federico M. Lentivirus Gene Engineering Protocols (Methods in Molecular Biology). New Jersey: Humana Press, 2003
[14]
17 Tiscornia G, Singer O, Verma I M. Production and purification of lentiviral vectors. Nat Protoc, 2006, 1: 241-245？？
[15]
21 Mi Y, Xue Y, Yu W, et al. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship withchromosome karyotype. Leukemia Lymphoma, 2008, 49: 524-530？？
[16]
23 Kruh G D, Belinsky M G. The MRP family of drug efflux pumps. Oncogene, 2003, 22: 7537-7552？？
[17]
25 Adachi M, Reid G, John D. Schuetz. Therapeutic and biological importance of getting nucleotides out of cells: A case for the ABC transporters,MRP4 and 5. Adv Drug Deliver Rev, 2002, 54: 1333-1342
[18]
26 Wei X L, Ni H, Wang Q S, et al. Impact of STAT4 gene silencing on the expression profile of proteins in EL-4 cells. Chinese Sci Bull, 2009,54: 3265-3270？？
[19]
27 Tomari Y, Zamore P D. Perspective: Machines for RNAi. Gene Dev, 2005, 19: 517-529？？
[20]
28 Doi N, Zenno S, Ueda R, et al. Short-interfering-RNA-mediated gene silencing in mammalian cells requires Dicer and eIF2C translation initiationfactors. Curr Biol Jan, 2003, 13: 41-46
[21]
29 Choung S, Kim Y J, Kim S, et al. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys ResCommun, 2006, 342: 919-927？？
[22]
34 Levine B L, Humeau L M, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA,2006, 103: 17372-17377？？
[23]
35 Li M, Rossi J J. Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods MolBiol, 2005, 309: 261-272
[24]
37 Materna V, Liedert B, Thomale J, et al. Protection of platinum DNA adduct formation and reversal of cisplatin resistance by anti-MRP2hammerhead ribozymes in human cancer cells. Int J Cancer, 2005, 115: 393-402？？
[25]
1 J？ger W. Classical resistance mechanisms. Int J Clin Pharm Ther, 2009, 47: 46-48
[26]
5 Russel F G M, Koenderink G B, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): A versatile efflux transporter for drugs andsignalling molecules. Trends Pharmacol Sci, 2008, 29: 200-207？？
[27]
6 Murray D N, Smith J, Tanabe K, et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma andconfers resistance to irinotecan in vitro. Mol Cancer Ther, 2005, 4: 547-553？？
[28]
18 Sena-Esteves M, Tebbets J C, Steffens S, et al. Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods,2004, 122: 131-139？？
[29]
19 Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther, 2000, 7: 910-913？？
[30]
20 Kim D H, Lee N Y, Sung W J, et al. Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes.Acta Haematol, 2005, 114: 78-83？？
[31]
22 Koistinen P, Raty R, Itala M, et al. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML):The nationwide AML-92 study by the Finnish Leukaemia Group. Eur J Haematol, 2007, 78: 477-486？？
[32]
24 Yoshida M, Suzuki T, Komiya T, et al. Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lungcancer cells resistant to adriamycin. Int J Cancer, 2001, 94: 432-437？？
[33]
30 Andrew G, John A, Antigoni P, et al. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood, 2005,105: 2510-2518？？
[34]
31 Cockrell A S, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol, 2005, 105: 2510-2518
[35]
32 Sinn P L, Sauter S L, McCray Jr P B. Gene therapy progress and prospects: Development of improved lentiviral and retroviral vectors-design,biosafety, and production. Gene Ther, 2005, 12: 1089-1098？？
[36]
33 Li M J, James K, Li S, et al. Long-Term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triplecombination of anti-HIV shRNA, Anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther, 2005, 12: 900-909
[37]
36 Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia, 2009, 14: 3-9？？
[38]
38 Materna V, Stege A, Surowiak P, et al. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.Biochem Biophys Res Commun, 2006, 348: 153-157？？
[39]
39 Chen T, Deng C S. Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells. Int Immu, 2008, 8: 1006-1011？？
